TNFSF13B and systemic lupus erythematosus: Results from the ILLUMINATE-1 and -2 trials showed that treatment with tabalumab, a monoclonal antibody against both soluble and membrane-bound BAFF, did not meet the primary efficacy endpoint of SLE responder index (SRI)-5 in patients with active SLE but no renal involvement40,41, and pooled data from these two RCTs did not suggest beneficial effects of tabalumab on the renal outcomes42.